PMID- 35890180
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230308
IS  - 1424-8247 (Print)
IS  - 1424-8247 (Electronic)
IS  - 1424-8247 (Linking)
VI  - 15
IP  - 7
DP  - 2022 Jul 17
TI  - Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response 
      and Related Parameters in 354 Patients.
LID - 10.3390/ph15070883 [doi]
LID - 883
AB  - Chronic pruritus is a major symptom of atopic dermatitis (AD). Its 
      etiopathogenesis is complex, and an understanding of the driving factors of its 
      pathogenesis allows for the development of new molecule-targeted therapies. 
      Dupilumab, targeting and blocking interleukin-4 (IL-4) and interleukin-13 (IL-13) 
      molecules, has shown great efficacy in treating AD symptoms such chronic itching. 
      We performed a retrospective observational study to evaluate possible 
      chronic-itch-related characteristics and parameters in 356 AD patients who 
      received dupilumab. The objective of the study was to evaluate the factors 
      associated with the level of pruritus reported by patients at each of the 1575 
      detections in the form of the peak pruritus numerical rating scale (NRSpp) and 
      sleep disturbance numerical rating scale (NRSsd). We focused on: the eczema area 
      and severity index (EASI), dermatology life quality index (DLQI), 
      patient-oriented eczema measure (POEMS), eosinophilia, L-lactate dehydrogenase 
      (LDH), immunoglobulin E (IgE) and the time from the start of dupilumab therapy. 
      NRSpp fell from 8.6 (sd 1.7) at baseline to 1.7 (sd 2.3) at 36 months and NRSsd 
      from 7 (sd 3) to 0. Regarding the parameters that correlate with NRSpp, all the 
      parameters analysed were significantly correlated except for eosinophils (p = 
      0.136). In the multivariate analysis, both considering and not considering 
      treatment duration, the parameters were correlated (p < 0.001); EASI, DLQI, POEM, 
      and LDH significantly correlated with NRSpp (p < 0.001 for each, except for LDH p 
      = 0.003); while IgE tot lost significance (p = 0.337). Similar results were 
      obtained for the parameters correlating with NRSsd. Our results confirm the 
      efficacy of dupilumab on pruritus. The use of questionnaires such as DLQI and 
      POEM is advisable in clinical practice and is adequate for assessing the impact 
      of itching on AD. The low correlation of IgE and eosinophils, the ambiguity of 
      LDH levels with the level of pruritus, and a poor clinical validity and unclear 
      correlation with disease severity suggest a progressive abandonment of monitoring 
      of these values.
FAU - Mastorino, Luca
AU  - Mastorino L
AUID- ORCID: 0000-0001-7386-3219
AD  - Dermatologic Clinic, Department of Medical Sciences, University of Turin, Via 
      Cherasco 23, 10121 Turin, Italy.
FAU - Rosset, Francois
AU  - Rosset F
AD  - Dermatologic Clinic, Department of Medical Sciences, University of Turin, Via 
      Cherasco 23, 10121 Turin, Italy.
FAU - Gelato, Federica
AU  - Gelato F
AD  - Dermatologic Clinic, Department of Medical Sciences, University of Turin, Via 
      Cherasco 23, 10121 Turin, Italy.
FAU - Ortoncelli, Michela
AU  - Ortoncelli M
AD  - Dermatologic Clinic, Department of Medical Sciences, University of Turin, Via 
      Cherasco 23, 10121 Turin, Italy.
FAU - Cavaliere, Giovanni
AU  - Cavaliere G
AD  - Dermatologic Clinic, Department of Medical Sciences, University of Turin, Via 
      Cherasco 23, 10121 Turin, Italy.
FAU - Quaglino, Pietro
AU  - Quaglino P
AD  - Dermatologic Clinic, Department of Medical Sciences, University of Turin, Via 
      Cherasco 23, 10121 Turin, Italy.
FAU - Ribero, Simone
AU  - Ribero S
AD  - Dermatologic Clinic, Department of Medical Sciences, University of Turin, Via 
      Cherasco 23, 10121 Turin, Italy.
LA  - eng
PT  - Journal Article
DEP - 20220717
PL  - Switzerland
TA  - Pharmaceuticals (Basel)
JT  - Pharmaceuticals (Basel, Switzerland)
JID - 101238453
PMC - PMC9318403
OTO - NOTNLM
OT  - atopic dermatitis
OT  - dupilumab
OT  - itching
OT  - pruritus
OT  - quality of life
COIS- The authors declare no conflict of interest.
EDAT- 2022/07/28 06:00
MHDA- 2022/07/28 06:01
PMCR- 2022/07/17
CRDT- 2022/07/27 01:38
PHST- 2022/05/15 00:00 [received]
PHST- 2022/06/16 00:00 [revised]
PHST- 2022/07/15 00:00 [accepted]
PHST- 2022/07/27 01:38 [entrez]
PHST- 2022/07/28 06:00 [pubmed]
PHST- 2022/07/28 06:01 [medline]
PHST- 2022/07/17 00:00 [pmc-release]
AID - ph15070883 [pii]
AID - pharmaceuticals-15-00883 [pii]
AID - 10.3390/ph15070883 [doi]
PST - epublish
SO  - Pharmaceuticals (Basel). 2022 Jul 17;15(7):883. doi: 10.3390/ph15070883.